<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">20839898</PMID>
      <DateCompleted>
        <Year>2010</Year>
        <Month>12</Month>
        <Day>23</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>20</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1179-1934</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>24</Volume>
            <Issue>10</Issue>
            <PubDate>
              <Year>2010</Year>
              <Month>Oct</Month>
            </PubDate>
          </JournalIssue>
          <Title>CNS drugs</Title>
          <ISOAbbreviation>CNS Drugs</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Dalfampridine extended release: in multiple sclerosis.</ArticleTitle>
        <Pagination>
          <StartPage>883</StartPage>
          <EndPage>891</EndPage>
          <MedlinePgn>883-91</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.2165/11205910-000000000-00000</ELocationID>
        <Abstract>
          <AbstractText>Dalfampridine extended release (ER) is an orally administered formulation of dalfampridine (fampridine, 4-aminopyridine), a potassium channel antagonist indicated for the improvement in walking ability in patients with multiple sclerosis (MS). Oral dalfampridine ER improved walking ability in patients with MS in three randomized, double-blind trials of up to 15 weeks' duration. In a phase II trial, percentage improvements in walking speed on the Timed 25-Foot Walk (T25FW) test (primary endpoint) were not significant versus baseline or placebo during treatment with dalfampridine ER 10, 15 or 20 mg twice daily. However, according to a post hoc analysis, response rates were significantly higher with dalfampridine ER than placebo, with a consistent mean improvement in walking speed of 25-29% seen in the pooled results from dalfampridine ER responders during the double-blind treatment period. In two phase III trials, the proportion of timed walk responders (primary endpoint) was significantly greater with dalfampridine ER 10 mg twice daily than with placebo, with improvements in walking speed of approximately 25% seen during dalfampridine ER treatment amongst timed walk responders. Interim results of noncomparative extensions of the two phase III trials showed that consistent improvements in walking speed were sustained above baseline for up to 2.5 years of dalfampridine ER treatment. Oral dalfampridine ER 10 mg twice daily was generally well tolerated in patients with MS, according to the results of the three randomized, double-blind, placebo-controlled trials.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Chwieduk</LastName>
            <ForeName>Claudine M</ForeName>
            <Initials>CM</Initials>
            <AffiliationInfo>
              <Affiliation>Adis, a Wolters Kluwer Business, Auckland, New Zealand. demail@adis.co.nz</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Keating</LastName>
            <ForeName>Gillian M</ForeName>
            <Initials>GM</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>New Zealand</Country>
        <MedlineTA>CNS Drugs</MedlineTA>
        <NlmUniqueID>9431220</NlmUniqueID>
        <ISSNLinking>1172-7047</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D003692">Delayed-Action Preparations</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D026902">Potassium Channel Blockers</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>BH3B64OKL9</RegistryNumber>
          <NameOfSubstance UI="D015761">4-Aminopyridine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D015761" MajorTopicYN="N">4-Aminopyridine</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003692" MajorTopicYN="N">Delayed-Action Preparations</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009103" MajorTopicYN="N">Multiple Sclerosis</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D026902" MajorTopicYN="N">Potassium Channel Blockers</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2010</Year>
          <Month>9</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2010</Year>
          <Month>9</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2010</Year>
          <Month>12</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">20839898</ArticleId>
        <ArticleId IdType="doi">10.2165/11205910-000000000-00000</ArticleId>
        <ArticleId IdType="pii">6</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Nature. 1980 Feb 7;283(5747):570-2</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7354839</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Neuroscience. 1997 Mar;77(2):553-62</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9472411</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Neurologist. 2009 May;15(3):161-2</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19430274</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brain. 2000 Jan;123 ( Pt 1):171-84</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10611131</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brain Res. 1978 Sep 22;153(2):307-18</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">210882</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clin Ther. 2009 Feb;31(2):328-35</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19302905</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clin Ther. 2009 Oct;31(10):2206-14</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19922891</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clin Neuropharmacol. 1993 Jun;16(3):195-204</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8504436</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Practitioner. 1964 Apr;192:540-2</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14143329</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pharmacol Rev. 2005 Dec;57(4):473-508</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16382104</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mult Scler. 2007 Apr;13(3):357-68</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17439905</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brain Res. 1986 Jan 15;363(1):1-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3004637</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Proc Natl Acad Sci U S A. 2004 Oct 5;101 Suppl 2:14599-606</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15306684</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Neurology. 2008 Oct 7;71(15):1134-41</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18672472</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Neurology. 1997 Apr;48(4):817-21</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9109861</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Neurol Sci. 1993 Jun;116(2):220-6</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8336169</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ann Pharmacother. 2008 Oct;42(10):1458-65</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18780812</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ann Neurol. 2001 Jul;50(1):121-7</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11456302</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lancet. 2009 Feb 28;373(9665):732-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19249634</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pharmacol Ther. 2006 Jul;111(1):224-59</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16472864</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Biol Chem. 2009 Dec 25;284(52):36453-36461</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19850918</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Neurol Sci. 1998 Jul 15;159(1):102-6</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9700711</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Clin Pharmacol. 2010 Feb;50(2):151-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19966074</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Muscle Nerve. 1980 Mar-Apr;3(2):105-11</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6245354</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brain Res Bull. 1989 Jan;22(1):47-52</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2540887</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Neurology. 1994 Jun;44(6):1054-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8208399</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Expert Opin Investig Drugs. 2009 Dec;18(12):1807-15</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19938897</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clin Ther. 2009 Oct;31(10):2215-23</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19922892</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mult Scler. 2010 Apr;16(4):406-11</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20215480</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
